BioCryst Pharmaceuticals | BCRX - 流动负债



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 2.03B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


流动负债 更改 日
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
Chugai Pharma JPY 392.19B 64.49B 2026-06
Daiichi Sankyo JPY 765.7B 119.32B 2026-06
DBV Technologies USD 54.3M 2.5M 2026-06
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novavax USD 330.57M 11.89M 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06